Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

1.895 +0.005 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,366,677
Open 1.950
Bid (Size) 1.900 (3)
Ask (Size) 1.920 (1)
Prev. Close 1.890
Today's Range 1.885 - 1.970
52wk Range 1.460 - 3.260
Shares Outstanding 66,497,370
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Are Xeris Biopharma Shares Moving Monday?
Xeris Biopharma shares are up Monday after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics. Xeris said it will work with Beta Bionics to develop and... 
Via Benzinga
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
From Xeris Biopharma Holdings, Inc.
Via Business Wire

Performance

YTD
-16.34%
-16.34%
1 Month
-7.11%
-7.11%
3 Month
-23.28%
-23.28%
6 Month
+2.43%
+2.43%
1 Year
-21.04%
-21.04%

More News

Read More
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics
Via ACCESSWIRE
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Outlook For Xeris Biopharma Holdings
Via Benzinga
Why Xeris Biopharma Shares Are Trading Higher Today
Via Benzinga
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For March 6, 2024
Via Benzinga
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down
Via InvestorPlace
Why Is Xeris Biopharma (XERS) Stock Up 12% Today?
Via InvestorPlace
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
From Xeris Biopharma Holdings, Inc.
Via Business Wire
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Via InvestorPlace
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Xeris Biopharma Updates Its Outlook for 2023
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports Third Quarter 2023 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Earnings Scheduled For November 9, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.